Bactobio (private company)
See something wrong or missing? Let us know
Offices:London
Industry:BiotechHealth services
Business model:B2B
Bactobio uses synthetic biology, next-generation sequencing, and machine learning to culture the 99 per cent of microbes that have previously been unculturable.
Investors:
we tracked 4 investors
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
values in USD
Investments 7.33M
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Companies with similar profile to Bactobio
| Name | Criteria | |
|---|---|---|
 |
iLoF
57%
|
|
 |
Monocl
57%
|
|
 |
Veritas Intercontinental
57%
|
|
 |
PEP-Therapy
57%
|
|
|
DeepLife
57%
|
|
|
Navinci Diagnostics
57%
|
|
|
Biomemory
57%
|
|
|
Biorelate
57%
|
|
 |
Atai Life Sciences
52%
|
|
|
Cinclus Pharma
52%
|
|
Belgium
Netherlands
Austria
Switzerland
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Ireland
Italy
Portugal